NEW YORK (GenomeWeb News) – Illumina said today that its board of directors has approved a new stock buy-back program that authorizes the firm to repurchase up to $75 million of its outstanding common stock.

Illumina said that it has terminated a previously announced $120 million repurchase program after repurchasing $70.7 million of outstanding common stock in 2008.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.